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The aim of the present study was to develop tizanidine controlled release matrix. Formulations were 
designed using central composite method with the help of design expert version 7.0 software. Avicel pH 
101 in the range of 14-50% was used as a filler, while HPMC K4M and K100M in the range of 25-55%, 
Ethylcellulose 10 ST and 10FP in the range of 15 - 45% and Kollidon SR in the range of 25-60% were 
used as controlled release agents in designing different formulations. Various physical parameters 
including powder flow for blends and weight variation, thickness, hardness, friability, disintegration 
time and in-vitro release were tested for tablets. Assay of tablets were also performed as specified in USP 
35 NF 32. Physical parameters of both powder blend and compressed tablets such as compressibility 
index, angle of repose, weight variation, thickness, hardness, friability, disintegration time and assay 
were evaluated and found to be satisfactory for formulations K4M2, K4M3, K4M9, K100M2, K100M3, 
K100M9, E10FP2, E10FP9, KSR2, KSR3 & KSR9. In vitro dissolution study was conducted in 900 ml 
of 0.1N HCl, phosphate buffer pH 4.5 and 6.8 medium using USP Apparatus II. In vitro release profiles 
indicated that formulations prepared with Ethocel 10 standard were unable to control the release of drug 
while formulations K4M2, K100M9, E10FP2 & KSR2 having polymer content ranging from 40-55% 
showed a controlled drug release pattern in the above mentioned medium. Zero-order drug release 
kinetics was observed for formulations K4M2, K100M9, E10FP2 & KSR2. Similarity test (f2) results for 
K4M2, E10FP2 & KSR2 were found to be comparable with reference formulation K100M9. Response 
Surface plots were also prepared for evaluating the effect of independent variable on the responses. 
Stability study was performed as per ICH guidelines and the calculated shelf life was 24-30 months for 
formulation K4M2, K100M9 and E10FP2.
Uniterms: Tizanidine/controlled release. Hydroxypropyl methylcellulose/controlled release agent. 
Ethylcellulose/controlled release agent. Kollidon SR/controlled release agent. Tablets/controlled release.
O objetivo do presente estudo foi desenvolver matriz de de tizanidina de liberação controlada. As 
formulações foram projetadas usando o método do componente, central com a ajuda de software Design 
expert®, versão 7.0. Utilizou-se Avicel pH 101, no intervalo de 14-50%, como material de preenchimento, 
enquanto HPMC K4M e K100M, no intervalo de 25-55%, Etilcelulose 10 ST e 10FP, no intervalo de 
15-45% e Kollidon SR, na faixa de 25-60% foram utilizados como agentes de liberação controlada, 
no planejamento de formulações diferentes. Vários parâmetros físicos, incluindo o fluxo de pó para 
as misturas e variação de peso, espessura, dureza, friabilidade, tempo de desintegração e liberação 
in vitro, foram testados para comprimidos. Ensaios dos comprimidos foram, também, realizados, tal 
como especificado em USP 35 NF 32. Avaliaram-se os parâmetros físicos de ambos, mistura em pó e 
comprimidos, como índice de compressibilidade, ângulo de repouso, variação de peso, espessura, dureza, 
friabilidade, tempo de desintegração e de ensaio, considerando-os satisfatórios para as formulações K4M2, 
K4M3, K4M9, K100M2, K100M3, K100M9, E10FP2, E10FP9, KSR2, KSR3 e KSR9. O estudo de 
dissolução in vitro foi realizado em 900 mL de HCl 0,1 N, tampão de fosfato pH 4,5 e meio 6,8, usando 
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aparelho USP II. Os perfis de liberação in vitro indicaram que as formulações preparadas com Ethocel 
10 padrão não foram capazes de controlar a liberação do fármaco, enquanto as formulações K4M2, 
K100M9, E10FP2e KSR2, com teor de polímero variando entre 40 e 55% apresentaram padrão de 
liberação controlada de fármaco no meio anteriormente mencionado. Observou-se cinética de liberação 
de fármaco de ordem zero para as formulações K4M2 , K100M9, E10FP2 e KSR2. Resultados do teste 
de similaridade (f2) para K4M2, E10FP2 e KSR2 foram comparáveis com a formulação de referência 
K100M9. Gráficos de superfície de resposta também avaliaram o efeito da variável independente sobre 
as respostas. Estudo de estabilidade foi realizado conforme as diretrizes do ICH e a vida de prateleira 
calculada foi de 24-30 meses para as formulações K4M2, K100M9 e E10FP2.
Unitermos: Tizanidina/liberação controlada.Hidroxipropilmetilcelulose/agente de liberação controlada. 
Etilcelulose/agente de liberação controlada. Kollidon SR./agente de liberação controlada. Comprimidos/
liberação controlada.
INTRODUCTION
Controlled release formulations of drugs may 
increase their therapeutic benefits, minimize side effects 
and enhance the patient compliance, therefore the overall 
disease management will be improved. Matrix based 
drug release systems offer many advantages such as 
the combination of matrix former and other materials 
can help in correlating the release characteristics to the 
requirements of drug and disease condition (Wilson, 
Crowley, 2011).
Tizanidine hydrochloride is an imidazoline derivative. 
It is a white to off white fine crystalline and odorless 
powder which is slightly soluble in water and methanol. 
Its solubility in water decreases with the increase in pH 
(Moffat, Osselton, Widdop, 2011). Acts on α2 receptors 
that are centrally located and produces a myotonolytic 
response on skeletal muscle (Wagstaff, Bryson, 1997) 
It acts mainly at spinal and supraspinal levels to inhibit 
excitatory inter neuron and is used for the symptomatic 
relief of spasticity associated with multiple sclerosis or with 
spinal cord injury or disease (Sweetman, 2009). It is also 
used in relieving pain with many disorders like myofascial 
(Meythaler et al., 2001), refractory and neuropathic pain, 
chronic tension type headache and chronic daily headache 
(Saper et al., 2002). After oral administration, tizanidine 
is widely absorbed from the gastrointestinal tract (53 to 
66%). Peak plasma concentration is achieved within 1 to 
2 h. It has a bioavailability of about 34% to 40% and has a 
half-life of 2.5 h. Protein binding of tizanidine is 30% and 
it undergoes rapid and extensive first-pass metabolism in 
the liver (approximately 95% of a dose) (Shanker et al., 
2009). The therapeutic dose of tizanidine is 2 mg and 
4 mg twice a day. The maximum recommended dose is 
36 mg/day (Kulkarni, Babu, 2012). The short half-life, 
low bioavailability and extensive first-pass metabolism 
make tizanidine a good candidate for the development of 
controlled release formulations.
In the present study controlled release formulations 
of tizanidine hydrochloride were designed using different 
viscosity grades of hydroxopropyl methylcellulose, ethyl 
cellulose and Kollidon® SR. HPMC is an important 
hydrophilic polymer extensively used for controlled 
release dosage forms development (Siepmann, Streubel, 
Peppas, 2002). Its fast gel forming characteristics not 
only control the initial release but also exert sustained 
release effect through strong viscous gel formation (Reza, 
Quadir, Haider, 2003). Moreover, its non-toxic nature, 
easy compressibility made it ideal for controlled release 
formulations of many drugs (Shoaib et al., 2010). Ethyl 
cellulose is also a nontoxic, inert hydrophobic polymer 
widely used in sustained release formulations and to 
control the dissolution rate of drugs (Quadir et al., 2005). 
As a matrix forming excipient for controlled release 
formulations Kollidon® SR is also an extensively used 
polymer consisting of 80% water insoluble poly(vinyl 
acetate) with a molecular weight of about 450.000 and 
about 20% water soluble poly(vinyl pyrrolidone), named 
as Kollidon® 30 (Strübing, Metz, Mäder, 2008). Many 
researchers (Draganoiu, Andheria, Sakr, 2001; Shao 
et al., 2001) used Kollidon® SR to delay the release of 
highly water soluble drugs such as propranolol HCl, 
diphenhydramine HCl etc., with low friability and high 
crushing strengths at low compression pressure (Kolter, 
2002).
Response surface methodology applied for 
illustration of effect of independent variables (such 
as polymers and fillers) on the dependent variables or 
responses (such as disintegration time and drug release). 
Response surface methodology (RSM) is a statistical tool 
for optimization of multifactor experiments (Hamsaveni, 
Prapulla, Divakar, 2001; Chiang, Chang, Shieh, 2003; 
Zhang et al., 2007). It is used to illustrate the correlation 
between independent variables and responses (Vicente 
et al., 1998). RSM require less effort with minimum 
number of trials as compare to other approaches (Liyana-
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Pathirana, Shahidi, 2005; Xiong et al., 2009). Central 
composite rotatable design (CCRD), is one of the design 
approaches in RSM, was developed by Box and Wilson 
(Box, Wilson, 1951) and later improvement has been 
made in this design by Box and Hunter (Box, Hunter, 
1957). CCRD is an effective optimization technique 
which enables to recognize optimum responses around 
center points through its rotatable characteristics (Zhang 
et al., 2010 a).
The aim of present work is to develop controlled 
release tizanidine matrix tablets using different polymers 
i.e., HPMC, Ethocel and Kollidon® SR, by direct 
compression method. Formulation of controlled release 
tizanidine tablets with these polymers using software 
Design expert® and application of response surface 
models, has not been reported earlier. Study showed 
importance and give a detailed analysis of work which 
proved formulation of tizanidine with hydrophilic and 
hydrophobic polymers.
MATERIAL AND METHODS
Material
The following materials were used: tizanidine 
hydrochloride (Novartis Pharma, Karachi), HPMC K4M 
& K100M, Ethocel 10 Standard Premium and Ethocel 10 
FP (Colorcon, England), Kollidon SR (BASF, Germany) 
Avicel PH 101 (FMC Corporation, USA) and magnesium 
stearate (Dow Chemical, USA).
Methods
Calculation of dose for controlled release tizanidine 
tablets
The total dose for tizanidine controlled release tablet 
can be calculated by using the following equation (Shoaib 
et al., 2010).
 
t n d 1
2
D D 1( )0.693 T / t= + ×  Eq (1)
where Dt is the prolonged action dose, Dn is the normal 
dose and Td is a required maintenance time.
For tizanidine hydrochloride, immediate release 
dose (Dn) is 4mg and half-life is 2.5 hours. Therefore, for 
a controlled release during 24h (Td), 30 mg of tizanidine 
(equivalent to 34 mg of tizanidine hydrochloride) per 
tablet was taken.
Preparation of tablets
Formulations were designed by using a software 
Design expert®. Different formulations of HPMC 
viscosity grades of K4M & K100M, Ethocel 10 ST 
(standard grade) & 10 FP(fine particle grade) and 
Kollidon SR were prepared by direct compression 
method. Each tablet containing 34 mg of tizanidine 
hydrochloride (equivalent to 30 mg of tizanidine) and 
2mg of magnesium stearate, while polymers HPMC 
K4M & K100M ranging from 25 to 55%, Ethocel 10ST 
& 10 FP (15% to 45%) and Kollidon SR (25 to 60%) were 
used as independent variable (X1) and Avicel PH 101(14 
to 50% in HPMC formulations, 26 to 48% in Ethocel 
formulations and 8-51% in Kollidon SR formulations) was 
used as second independent variable (X2). Formulation 
excipients and active ingredient were passed through 
40-mesh size sieve and accurately weighed. Excipients 
and active ingredient of each formulation were blended 
by tumbling method in a polybag for about 8-10 min and 
then compressed on manually operated single punch tablet 
press (Korsch Erweka, Frankfurt, Germany). Convex 
round shaped punch was used and tablets were pressed in 
a range of 96 to 126 mg.
Experimental design
To find out the optimum level of variable, a two 
factor with five levels CCD was developed. It consists of 
factorial points at two levels, axial points at two levels and 
center point. Hence, independent variables (X1:Polymer 
and X2: Avicel PH 101) at five levels were considered. 
The levels were -α, -1, 0,1 and +α. The alpha value (1.414) 
was taken to execute design rotatibility. Disintegration 
time and drug release both at 2 and 8 h were selected as 
responses. The coded and actual values of variables are 
given in Table I. By using Design Expert software (Version 
7, Stat-Ease Inc., Minneapolis, MN), CCD generated a 
total of nine (9) experiments with four factorial, four axial 
and one center point. Hao et al also used central composite 
response surface design with five replicated center points 
(Hao et al., 2012).
Micromeritic Study
Micromerit ic properties of powder blends 
such as tapped density, bulk density, Hausner’s ratio, 
compressibility index and angle of repose were evaluated 
using the procedure specified in US pharmacopeia 
(USP35-NF30, 2012).
Hausner’s ratio, compressibility index and angle of 
repose were calculated by the following equations.
 
tapped bulkHausner’s ratio (ρ /ρ )=  Eq (2)
tapped bulk tappedCompressibility Index 100[ ( )ρ ρ /ρ ]= × −  Eq (3)
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TABLE I - A two factor central composite rotatable design of experiments for tizanidine formulations
Formulation 
Code
Coded factor level Factors Amount 
(% )
Factors Amount 
(mg) Total Wt. of
Tablet (mg)
Total wt.
adjusted (mg)X 1 X 2
HPMC K4M HPMC K4M Avicel PH 101 HPMC K4M Avicel PH 101 HPMC K4M Avicel PH 101
K4M 1 -1 -1 30.00 20.00 30.84 20.56 87.40 88
K4M 2 1 -1 50.00 20.00 51.40 20.56 107.96 108
K4M 3 -1 1 30.00 45.00 30.84 46.26 113.10 113
K4M 4 1 1 50.00 45.00 51.40 46.26 133.66 134
K4M 5 -1.414 0 25.86 32.50 26.58 33.41 95.99 96
K4M 6 1.414 0 54.14 32.50 55.66 33.41 125.07 125
K4M 7 0 -1.414 40.00 14.82 41.12 15.23 92.35 93
K4M 8 0 1.414 40.00 50.18 41.12 51.58 128.70 128
K4M 9 0 0 40.00 32.50 41.12 33.41 110.53 110
HPMC K100M HPMC K100M Avicel PH 101 HPMC K100M Avicel PH 101 HPMC K100M Avicel PH 101  
K100M 1 -1 -1 30.00 20.00 30.84 20.56 87.40 88
K100M 2 1 -1 50.00 20.00 51.40 20.56 107.96 108
K100M 3 -1 1 30.00 45.00 30.84 46.26 113.10 113
K100M 4 1 1 50.00 45.00 51.40 46.26 133.66 134
K100M 5 -1.414 0 25.86 32.50 26.58 33.41 95.99 96
K100M 6 1.414 0 54.14 32.50 55.66 33.41 125.07 125
K100M 7 0 -1.414 40.00 14.82 41.12 15.23 92.35 93
K100M 8 0 1.414 40.00 50.18 41.12 51.58 128.70 128
K100M 9 0 0 40.00 32.50 41.12 33.41 110.53 110
Ethocel 10 Standard Ethocel 10 ST Avicel PH 101 Ethocel 10 ST Avicel PH 101 Ethocel 10 ST Avicel PH 101  
E10ST 1 -1 -1 20.00 30.00 22.00 33.00 91.00 91
E10ST 2 1 -1 40.00 30.00 44.00 33.00 113.00 113
E10ST 3 -1 1 20.00 45.00 22.00 49.50 107.50 108
E10ST 4 1 1 40.00 45.00 44.00 49.50 129.50 130
E10ST 5 -1.414 0 15.86 37.50 17.45 41.25 94.70 95
E10ST 6 1.414 0 44.14 37.50 48.56 41.25 125.81 126
E10ST 7 0 -1.414 30.00 26.89 33.00 29.58 98.58 99
E10ST 8 0 1.414 30.00 48.11 33.00 52.92 121.92 122
E10ST 9 0 0 30.00 37.50 33.00 41.25 110.25 110
Ethocel 10 FP Ethocel 10 FP Avicel PH 101 Ethocel 10 FP Avicel PH 101 Ethocel 10 FP Avicel PH 101  
E10FP 1 -1 -1 20.00 30.00 22.00 33.00 91.00 91
E10FP 2 1 -1 40.00 30.00 44.00 33.00 113.00 113
E10FP 3 -1 1 20.00 45.00 22.00 49.50 107.50 108
E10FP 4 1 1 40.00 45.00 44.00 49.50 129.50 130
E10FP 5 -1.414 0 15.86 37.50 17.45 41.25 94.70 95
E10FP 6 1.414 0 44.14 37.50 48.56 41.25 125.81 126
E10FP 7 0 -1.414 30.00 26.89 33.00 29.58 98.58 99
E10FP 8 0 1.414 30.00 48.11 33.00 52.92 121.92 122
E10FP 9 0 0 30.00 37.50 33.00 41.25 110.25 110
Kollidon SR KSR Avicel PH 101 KSR Avicel PH 101 KSR Avicel PH 101  
KSR 1 -1 -1 30.00 15.00 33.00 16.50 85.50 86
KSR 2 1 -1 55.00 15.00 60.50 16.50 113.00 113
KSR 3 -1 1 30.00 45.00 33.00 49.50 118.50 118
KSR 4 1 1 55.00 45.00 60.50 49.50 146.00 146
KSR 5 -1.414 0 24.82 30.00 27.30 33.00 96.30 96
KSR 6 1.414 0 60.18 30.00 66.20 33.00 135.20 135
KSR 7 0 -1.414 42.50 8.79 46.75 9.67 92.42 92
KSR 8 0 1.414 42.50 51.21 46.75 56.33 139.08 139
KSR 9 0 0 42.50 30.00 46.75 33.00 115.75 116
Use of hydrophilic and hydrophobic polymers for the development of controlled release tizanidine matrix tablets 803
 tan(α) height / 0.5 base=  Eq (4)
where ρtapped and ρbulk were the tapped and bulk densities of 
blends, respectively and a was the angle of repose.
Evaluation of tizanidine tablets
Tizanidine tablets were evaluated using several 
physical parameters including weight variation, hardness, 
thickness, friability and disintegration. Weight variation 
was performed by using digital balance (Sartorius CP 
224S, Germany) for all compressed formulations. Tablet 
hardness was determined using Fujiwara Seisakusho 
tablet hardness tester, Ogawa Seiko Co Ltd, Tokyo, 
Japan. Tablet disintegration test were performed using 
USP basket rack assembly (Erweka disintegration 
tester, ZT2, Heusenstamm, Germany). Tablet friability 
was carried out using Roche type friabilator (H Jurgens 
friabilator GmbH & Co. D-2800 Breman, Germany) 
(USP 35-NF 30, 2012).
Swelling studies
Swelling studies of tablets were performed by gently 
placing a tablet (using a wire) in a beaker containing 
about 250 mL of distilled water at room temperature. The 
weights of swollen tablets (after absorbing excess water 
through a filter paper) were recorded at 1, 2, 3, 4, 6 and 
8 h. Water uptake (%) was expressed as a percentage of 
initial tablet weight (Cao et al., 2005).
 t o
0
W W
% S 100
W
−
= ×   Eq (5)
where S is the swelling of tablet, Wt is the weight of 
swollen tablet and Wo is the initial weight of tablet.
Dissolution studies
Dissolution studies were performed by placing 
six tablets of each formulation in 900 mL of dissolution 
medium at 37±0.5 ºC using a USP apparatus II dissolution 
tester (DT 600, Erweka, Germany). Paddles were rotated 
at 100rpm and the medium used was 0.1 N HCl, Phosphate 
buffer at pH 4.5 & 6.8. Samples were analyzed using UV-
VIS spectrophotometer (UV-1800, Shimadzu, Kyoto, 
Japan) at 320 nm by withdrawing 5 mL of aliquots at 
regular time interval of 30min, 1, 2, 3, 4, 5, 6, 8, 10, 12, 
16, 20 and 24h and filtered using a 0.45 μm filter. These 
aliquots were replaced by the same medium previously 
maintained at 37±0.5 ºC.
Quantification of tizanidine in the formulation
Drug quantification was performed using high 
performance liquid chromatographic method. The mobile 
phase was composed of acetonitrile and buffer solution 
of sodium 1-petanesulfonate in a ratio of 4:1 (buffer 
solution was prepared by adding 3.5g of sodium 1-pentane 
sulfonate in 1 liter of water and pH was adjusted with 
phosphoric acid solution or 1 N sodium hydroxide at pH 
3.0±0.05). The HPLC system consists of a pump LC- 10 
AT VP, Communication Bus Module CBM 102, and a UV 
detector SPD 10-A VP (Shimadzu Corp, Tokyo, Japan). 
The column used was Intersil ODS-3, 4.6 x 250mm which 
was maintained at 50 °C in a column oven (CTO-10A, 
Shimadzu Corp., Kyoto, Japan) with a flow rate of 
1 mL/min. Injection volume was 10 µL and detection wave 
length was 230 nm. Software used was class GC 10 ver. 2.0 
(1993-2000), (Shimadzu Corp., Kyoto, Japan) was used 
for data processing (USP 35-NF 30, 2012).
Stability studies
The optimized formulations were then subjected to 
accelerated stability study as per ICH guidelines i.e. by 
placing tablets in a Stability chamber ((Binder GMBH 
Bergster, Tullingen,Germany) at 40±2 °C and 75±5% 
RH (ICH, 2003). The samples were removed and tested 
at 0, 1, 3 and 6 months and different physico-chemical 
parameters like hardness, friability, disintegration, 
dissolution and quantification were assessed. The shelf life 
was calculated using R-Gui version 2.15.2 (stab) package 
(The R Foundation for Statistical Computing).
Data Analysis
•	 Model-dependent methods
In order to propose mechanism of drug release from 
these formulations, in vitro dissolution profiles data were 
fitted into different kinetic models. These models were 
zero order (cumulative amount of drug released vs time), 
first-order (log cumulative percentage of drug remaining 
vs time), Higuchi’s (cumulative percentage of drug 
released vs square root of time), Hixson–Crowell (cube 
root percent drug remaining vs time) and Korsmeyer’s 
(log cumulative percentage of drug released vs log time).
•	 Zero order equation:
 Qt = Kot Eq (6)
where Ko is the zero-order rate constant expressed in units 
of concentration/time, t is the time in hours, and Qt is the 
amount of drug release in time t. 
•	 First-order equation:
 LogQt = log Qo – kt /2.303 Eq (7)
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where Qt is the amount released at time t, Qo is the initial 
amount of drug in solution and k is the first order rate 
constant and t is the time.
•	 Higuchi’s equation:
 Q = kt1/2 Eq (8)
where k is the release rate constant and t is the time in 
hours. Hence, the drug release rate is proportional to the 
reciprocal of the square root of time (David, 2002).
•	 Hixson–Crowell Cube Root equation
 Qo1/3 – Qt1/3 = KHC × t Eq (9)
where KHC is the Hixson–Crowell rate constant, Qo is the 
intial amount of drug and Qt is the amount of drug release 
at time t (Higuchi, 1963).
For zero order, Higuchi, and Hixson–Crowell model, 
the rate constant were also calculated that is simply equal 
to the slope of the straight line:
 Ko = Slope Eq (10)
Below is showed the equation used for first-order 
rate constant
 K = –Slope × 2.303 Eq (11)
Korsmeyer’s equation (Power law),
 Mt / M∞ = Ktn Eq (12)
where Mt is the amount of drug released at time t, M∞ 
is the amount of drug released after infinite time (total 
drug in a dosage form), K is the Korsmeyer’s dissolution 
rate constant and n is the release exponent which was 
calculated through the slope of the straight line which 
characterizes the mechanism of release (Hixson, Crowell, 
1931).
For matrix devices that are cylindrical-shaped, if the 
exponent n value is 0.45 it is indicative of Fickian release 
(case I), for non-Fickian release (anomalous) it should be 
>0.45 but <0.89, value of 0.89 is indicative of case II (zero 
order) release, and >0.89 is super case II type of release 
(Korsmeyer et al., 1983).
Model Independent Method
•	 Similarity Factor (f2)
The similarity factor (f2) is a logarithmic reciprocal 
square root transformation of the sum of squared error 
and is a measurement of the similarity in the percent 
dissolution between the two curves:
( )
0.5
2
2 i i
1f 50 log 1 R T 100
N
−    
= × + − ×       ∑  Eq (13)
where Ri is the percent dissolved of referenced drug, Ti is 
the percent dissolved of test drug at each time point and 
N is the number of samples. Its value will be 100 where 
test and reference drug profiles are identical. Dissimilarity 
in profiles increases with the decrease in f2 (Costa, Sousa 
Lobo, 2001).
RESULTS AND DISCUSSION
Formulation of tizanidine matrix tablets
Tizanidine controlled release formulations were 
designed using software Design Expert version 7.0. The 
coded and actual quantities of individual content of tablet 
for different polymers i.e HPMC (K4M & K100M) Ethocel 
(10 ST & 10 FP) and Kollidon SR are shown in Table I. 
HPMC K4M and K100M formulations were assigned 
formulation code K4M and K100M as prefix followed 
by numeric number as suffix. Similarly, formulations 
containing Ethocel 10 Standard grade, Ethocel 10 fine 
particle grade and Kollidon SR were assigned formulation 
codes E10ST, E10FP and KSR, respectively and followed 
by a numeric number as suffix.
Evaluation of powder blends and tablets
Micromeritic evaluation of powder blends, 
Hausner’s ratio, compressibility index and angle of repose 
were calculated for the formulations and showed in Table 
II. The powder blends which comply with USP standard 
and categorized as Fair to Excellent, were chosen for 
compression and further studies. The formulations which 
complied with USP standards in terms of flow properties 
were K4M2, K4M3, K4M5, K4M9, K100M2, K100M 
3, K100M 5, K100M9, E10ST 2, E10ST 6, E10ST 9, 
E10FP 2, E10FP 3, E10FP 9, KSR 2, KSR 3, KSR 5 and 
KSR 9. These formulations were evaluated for physical 
parameters such as thickness, hardness, weight variation, 
friability, disintegration time and assay (Table III). The 
mean thickness and hardness of tablets were in the range 
of 3.67 ± 0.14 to 4.39 ± 0.18 mm and 3.40 ± 0.78 to 
12.92 ± 1.80kg, respectively. Powder flowability and 
level of powder in dye often regulate variation in tablet 
thickness (Davies, 1995). The hardness is an attribute 
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due to binding characteristic of the filler and the force 
of compression with which the ingredients have been 
compressed (Siddiqui, Nazzal, 2007). Weight variation 
was in the range of 95.74 ± 6.32 to 125.35 ± 4.53 mg. 
Friability of compressed formulations was < 1% except 
for formulations K4M5 and KSR5. Disintegration time 
of less than 4 hours was observed for K4M5, K100M5, 
E10ST 2, 6 & 9, E10FP3 and KSR 5 formulations. 
Early disintegration observed in formulation where the 
concentration of polymers was low, it seemed that low 
TABLE II - Micromeritic Properties of different formulation blends
Formulation 
code 
Mass Bulk Volume
Tapped 
volume
Bulk 
density 
Tapped 
density 
Haunser 
Ratio
Compressibility 
Index
Angle of 
repose
Flow 
properties 
according to 
(g) (mL) (mL) ( g/mL) (g/mL)  % θ USP 35
K4M 1 10.00 17.00 12.00 0.59 0.83 1.42 29.41 53.28 Poor
K4M 2 10.00 17.00 16.00 0.59 0.63 1.06 5.88 29.56 Excellent
K4M 3 10.00 19.00 16.00 0.53 0.63 1.19 15.79 36.32 Fair
K4M 4 10.00 20.00 14.00 0.50 0.71 1.43 30.00 49.83 Poor
K4M 5 10.00 20.00 16.00 0.50 0.63 1.25 20.00 38.39 Fair
K4M 6 10.00 20.00 14.00 0.50 0.71 1.43 30.00 53.99 Poor
K4M 7 10.00 17.00 12.00 0.59 0.83 1.42 29.41 54.21 Poor
K4M 8 10.00 18.00 12.00 0.56 0.83 1.50 33.33 58.18 V Poor
K4M 9 10.00 17.00 15.00 0.59 0.67 1.13 11.76 33.20 Good
K100M 1 10.00 17.00 11.00 0.59 0.91 1.55 35.29 60.79 V Poor
K100M 2 10.00 18.00 16.00 0.56 0.63 1.13 11.11 32.11 Good
K100M 3 10.00 20.00 17.00 0.50 0.59 1.18 15.00 33.28 Good
K100M 4 10.00 19.00 11.00 0.53 0.91 1.73 42.11 70.45 V V Poor
K100M 5 10.00 17.00 13.00 0.59 0.77 1.31 23.53 38.12 Fair
K100M 6 10.00 20.00 15.00 0.50 0.67 1.33 25.00 42.66 Passable
K100M 7 10.00 17.00 12.00 0.59 0.83 1.42 29.41 46.32 Poor
K100M 8 10.00 17.00 11.00 0.59 0.91 1.55 35.29 60.28 V Poor
K100M 9 10.00 18.00 17.00 0.56 0.59 1.06 5.56 27.19 Excellent
E10ST 1 10.00 24.00 16.00 0.42 0.63 1.50 33.33 61.24 V Poor
E10ST 2 10.00 23.00 19.00 0.43 0.53 1.21 17.39 38.13 Fair
E10ST 3 10.00 23.00 17.00 0.43 0.59 1.35 26.09 51.22 Poor
E10ST 4 10.00 22.00 15.00 0.45 0.67 1.47 31.82 58.54 V Poor
E10ST 5 10.00 23.00 15.00 0.43 0.67 1.53 34.78 64.87 V Poor
E10ST 6 10.00 24.00 21.00 0.42 0.48 1.14 12.50 34.25 Good
E10ST 7 10.00 24.00 18.00 0.42 0.56 1.33 25.00 43.30 Passable
E10ST 8 10.00 21.00 15.00 0.48 0.67 1.40 28.57 48.74 Poor
E10ST 9 10.00 22.00 18.00 0.45 0.56 1.22 18.18 37.34 Fair
E10FP 1 10.00 27.00 21.00 0.37 0.48 1.29 22.22 43.23 Passable
E10FP 2 10.00 28.00 24.00 0.36 0.42 1.17 14.29 32.12 Good
E10FP 3 10.00 29.00 24.00 0.34 0.42 1.21 17.24 37.75 Fair
E10FP 4 10.00 31.00 24.00 0.32 0.42 1.29 22.58 44.09 Passable
E10FP 5 10.00 31.00 22.00 0.32 0.45 1.41 29.03 53.37 Poor
E10FP 6 10.00 30.00 20.00 0.33 0.50 1.50 33.33 58.16 V Poor
E10FP 7 10.00 28.00 18.00 0.36 0.56 1.56 35.71 62.97 V Poor
E10FP 8 10.00 29.00 22.00 0.34 0.45 1.32 24.14 44.23 Passable
E10FP 9 10.00 31.00 26.00 0.32 0.38 1.19 16.13 37.32 Fair
KSR 1 10.00 19.00 14.00 0.53 0.71 1.36 26.32 51.55 Poor
KSR 2 10.00 19.00 18.00 0.53 0.56 1.06 5.26 27.19 Excellent
KSR 3 10.00 21.00 18.00 0.48 0.56 1.17 14.29 34.31 Good
KSR 4 10.00 22.00 16.00 0.45 0.63 1.38 27.27 47.5 Poor
KSR 5 10.00 18.00 15.00 0.56 0.67 1.20 16.67 39.25 Fair
KSR 6 10.00 22.00 15.00 0.45 0.67 1.47 31.82 57.86 V Poor
KSR 7 10.00 20.00 14.00 0.50 0.71 1.43 30.00 46.82 Poor
KSR 8 10.00 22.00 17.00 0.45 0.59 1.29 22.73 42.51 Passable
KSR 9 10.00 20.00 17.00 0.50 0.59 1.18 15.00 33.62 Good
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concentration of polymers was unable to control tablet 
disintegration upto 4 hours. It was also observed that 
tablets formulated with Ethocel 10 Standard grade were 
unable to control the disintegration that may be due to their 
larger particle size which allows water to penetrate inside 
the void spaces as reported by Crowley et al. (2004). Assay 
of all compressed formulations were within the limits as 
specified in USP (USP35-NF30, 2012).
Study of hydration behavior
Swelling studies revealed the swelling properties 
of tablets and studied as a function of polymers used in 
the study. The swelling behavior of a polymer enables 
the formation of swellable layer or the gel layer. The gel 
layer hindered movement of drug from inner dry layer and 
enable the release of drug only from the upper gel layer 
and causing a controlled release of drug. Formulations 
containing hydrophilic polymers swell well while the 
hydrophobic polymers showed less swelling behavior.
The results of swelling behavior with different 
polymers were shown in Figure 1. It is clear from the 
results that HPMC showed highest hydration ability 
as compared to Kollidon SR and Ethocel due to its 
hydrophilic nature. Formulation containing Ethocel 
showed least swelling among three tested polymers due 
to its higher hydrophobic nature. The data showed that by 
increasing the quantity of HPMC K4M and K100M, tablet 
swelling has been increased. Nerurkar et al., also noticed 
that increase in concentration of polymer in matrix will 
cause an increase of amount of water uptake (Nerurkar 
et al., 2005). Further, from these results it is also clear 
that with change of HPMC viscosity grade to higher side, 
swelling properties also enhanced.
In vitro drug release profiles
Tizanidine formulations release profiles in 0.1 N 
HCl, phosphate buffer pH 4.5 and 6.8 were presented 
in Figure 2, 3 and 4, respectively. Release profiles of 
tizanidine tablets in different dissolution media were not 
found significantly different. Amir and Ahmad (2010), 
also found the similar type of drug release behavior of 
tizanidine and tramadol modified release microparticles in 
0.1 N HCl and pH 6.8 phosphate buffer. It was found that 
formulations with Ethocel 10 standard grade were unable 
to control the release and nearly the entire drug has been 
released within 4 hours in the three dissolution media. 
According to Percolation theory, in a matrix formulation 
of hydrophilic drug and hydrophobic polymer, drug release 
TABLE III - Physical Evaluation and assay of tizanidine matrix
Formulation 
code
Thickness 
(mm)
Hardness 
(kg)
Weight Variation 
(mg)
Friablity 
(%)
Disintegration 
time (hrs)
Assay 
(%)
K4M 2 3.96 ± 0.10 4.81 ± 0.52 108.23 ± 2.80 0.76 4.82 98.76
K4M 3 4.05 ± 0.12 4.20 ± 0.38 113.21 ± 2.80 0.91 4.18 97.25
K4M 5 3.67 ± 0.14 3.74 ± 0.70 96.98 ± 5.00 1.14 3.55 96.38
K4M 9 3.99 ± 0.12 4.69 ± 1.18 110.71 ± 4.06 0.94 4.30 98.05
K100M 2 4.01 ± 0.14 5.87 ± 0.68 109.30 ± 3.66 0.57 6.87 98.37
K100M 3 4.03 ± 0.16 4.30 ± 0.70 113.37 ± 4.78 0.85 4.95 97.82
K100M 5  3.97 ± 0.16  4.04 ± 1.12  95.74 ± 6.32  0.99  3.73  98.61
K100M 9 3.98 ± 0.08 5.57 ± 0.76 110.27 ± 4.00 0.63 6.58 98.87
E10ST 2 4.01 ± 0.15 8.04 ± 1.86 113.54 ± 3.71 0.76 1.42 96.81
E10ST 6 4.39 ± 0.18 8.53 ± 2.26 125.35 ± 4.53 0.69 2.10 97.32
E19ST 9 4.05 ± 0.13 7.96 ± 1.57 109.85 ± 3.82 0.97 1.38 96.18
E10FP 2 3.99 ± 0.08 12.92 ± 1.80 113.77 ± 3.74 0.30 5.72 98.79
E10FP 3 4.00 ± 0.10 11.75 ± 2.14 109.46 ± 4.5 0.95 3.68 96.32
E10FP 9 3.98 ± 0.14 12.57 ± 2.30 110.82 ± 5.38 0.47 5.13 98.24
KSR 2 4.24 ± 0.10 5.01 ± 0.74 113.30 ± 3.04 0.29 7.52 98.39
KSR 3 4.07 ± 0.14 4.24 ± 0.88 118.97 ± 3.98 0.84 4.25 96.51
KSR 5 4.04 ± 0.12 3.40 ± 0.78 96.82 ± 5.28 1.53 3.15 95.23
KSR 9 4.20 ± 0.12 4.20 ± 0.58 116.05 ± 4.04 0.63 6.27 97.27
Use of hydrophilic and hydrophobic polymers for the development of controlled release tizanidine matrix tablets 807
FIGURE 1 - Hydration behavior of tizanidine matrix formulations containing (a) HPMC K4M (b) HPMC K100M (c) Ethocel 
10ST (d) Ethocel 10 FP (e) Kollidon SR.
was derived by dissolution of drug through capillaries 
composed of interconnecting drug particle cluster and 
pore network (Holman, Leuenberger, 1988). With more 
ethyl cellulose particles fewer pore networks were formed 
(Crowley et al., 2004) as the case with fine particles and 
retard the release while in case of coarser particles the 
more pore network will be formed that was unable to 
control the release of drug.
Formulations containing 25% or less of polymer 
(K4M5, K100M5, E10FP3 and KSR5) were also unable 
to retard the release and more than 90% of drug was 
available in dissolution media in 4 hours. Tablets with 
a polymer ratio of 30% (K4M3, K100M3 and KSR3) 
released about 80% of drug except in case of Ethocel 10 
FP (E10FP9) where 76% release was observed with 30% 
of polymer. K100M9 (HPMC K100M: 40% polymer) 
given a good controlled release profile. From K100M9 
formulation, around 40% drug released in 4h, 80% in 
8h and 98% in 24 hours. Similar type of profiles were 
observed in formulations K4M2 (50% polymer), E10FP2 
(40% polymer) and KSR2 (55% polymer) in which around 
45 to 53% drug released in 4 hours was observed, 82 to 
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85% drug released in 8 hours and 94 to 99% drug released 
in 24 hours. It was observed in all formulations that drug 
release has inverse relation with polymer concentration. 
Barakat, Elbagory and Almurshedi (2009) found that 
increase in the concentration of HPMC results in reduction 
in the release rate from carbamazepine matrix formulation 
and followed non-fickian diffusion which shifted to 
case II with the increase in HPMC ratio in formulation, 
showed significant contribution through erosin. Similarly, 
Baviskar, Sharma and Jain (2013) observed retard release 
of verapamil hydrochloride matrix tablet with increase 
in concentration of HPMC K15M and Eudragit RSPO. 
Reza, Quadir and Haider (2003) found increase in drug 
release rate with decreasing total polymeric content of 
matrix tablets of theophylline, diclofenac sodium and 
diltiazem hydrochloride by using plastic, hydrophobic 
and hydrophilic polymers. The release rate was much 
retarded in formulation K100M2 which contains 50% of 
polymer and around 80% of the drug release in 24 hours. 
Huang et al. (2004) had similar finding where release 
was incomplete from propranalol hydrochloride tablet 
containing high amount of HPMC.
FIGURE 2 - Drug release profiles of Tizanidine formulations in 0.1 N HCl containing (a) HPMC K4M (b) HPMC K100M (c) 
Ethocel 10ST (d) Ethocel 10FP (e) Kollidon SR.
Use of hydrophilic and hydrophobic polymers for the development of controlled release tizanidine matrix tablets 809
Drug release kinetics
Model dependent method
Drug release kinetics from tizanidine matrix 
tablets was described by various mathematical models 
and equations. The dissolution data was fitted to zero 
order, first order, Higuchi, Korsmeyer-Peppas and 
Hixon-Crowell to determine the mechanism of drug 
release. The Regression coefficients and release constants 
were calculated by DD-solver and shown in Table IV. 
DD Solver is an add-in program for Microsoft Excel® 
for dissolution data modeling and profile comparison 
(Zhang et al., 2010b). The dissolution data up to 8 hours 
were used for all formulations. The data selection was 
based on the data until the time which represent the 
dynamics of dissolution process (Polli et al., 1997). 
The tizanidine formulations which were best support 
the zero order release kinetics were K4M2, K100M9, 
E10FP2 and KSR2 as highest linearity values were 
observed in 0.1 N HCl, phosphate buffer pH 4.5 and 
6.8. Formulation, K100M2 although yielded zero-order 
but incomplete release kinetics. Bravo, Lamas and 
FIGURE 3 - Drug release profiles of tizanidine formulations in phosphate buffer pH 4.5 containing (a) HPMC K4M (b) HPMC 
K100M (c) Ethocel 10ST (d) Ethocel 10FP (e) Kollidon SR.
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Salomon (2002)  found zero order release kinetics for 
diclofenac sodium HPMC matrix tablets with highest 
regression coefficient values followed by Higuchi and 
first order. Sankalia Sankalia, Mashru (2008) have 
formulated glipizide matrix tablets with xanthan:MCC 
PH301 and xanthan:HPMC K4M:Starch 1500 with 
Korsmeyer–Peppas’ and zero-order release mechanism, 
respectively. Jan et al. (2011) successfully developed 
sustained release Ketoprofen tablets with different grades 
of Ethocel FP and found release kinetics nearly zero-
order. Sahoo et al. (2008) prepared controlled release 
propranalol hydrochloride tablet by direct compression 
with 40% Kollidon SR that showed a zero-order release 
kinetics.
The diffusional coefficient (n) obtained from 
Korsmeyers equation were in the range of > 0.45 to 
< 0.89 for K4M2, K100M9, E10FP2 and KSR2 which 
showed that drug was release through anomalous 
transport also known as non-Fickian release that was 
an indication that the release of drug is controlled by 
both diffusion and erosion mechanism (Peppas, 1985). 
This equation has also been used by many researchers 
FIGURE 4 - Drug release profiles of tizanidine formulations in phosphate buffer pH 6.8 containing (a) HPMC K4M (b) HPMC 
K100M (c) Ethocel 10ST (d) Ethocel 10FP (e) Kollidon SR.
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TABLE IV - Model dependent assessment of tizanidine formulations
 Zero order First order Higuchi Korsmeyer-Peppas Hixon-crowell
r2 K0(h-1) r2 K1(h-1) r2 KH(h-1/2) r2 n Kkp(h-n) r2 KHC(h-1/3)
0.1 N HCl          
K4M 2 0.996 11.586 0.964 0.192 0.972 26.792 0.982 0.641 21.498 0.976 0.055
K4M 3 0.930 17.217 0.951 0.923 0.978 42.347 0.991 0.226 63.683 0.974 0.180
K4M 9 0.992 13.355 0.984 0.259 0.994 31.333 0.994 0.526 30.089 0.992 0.072
K100M 2 0.994 8.310 0.977 0.115 0.971 19.058 0.985 0.726 13.342 0.983 0.034
K100M 3 0.927 16.894 0.972 0.566 0.970 40.719 0.976 0.358 50.441 0.980 0.146
K100M 9 0.997 10.830 0.969 0.170 0.971 24.870 0.986 0.713 17.794 0.979 0.049
E10FP 2 0.996 11.653 0.978 0.195 0.983 26.959 0.990 0.642 21.589 0.987 0.056
E10FP 9 0.927 15.951 0.995 0.526 0.978 38.660 0.989 0.325 50.353 0.991 0.139
KSR 2 0.991 12.287 0.975 0.215 0.981 28.472 0.987 0.629 23.277 0.985 0.061
KSR 3 0.778 17.573 0.979 1.821 0.862 44.177 0.919 0.117 77.467 0.936 0.191
KSR 9 0.938 15.559 0.991 0.449 0.981 37.471 0.987 0.363 46.104 0.996 0.119
pH 4.5         
K4M 2 0.997 11.257 0.971 0.182 0.975 25.919 0.988 0.686 19.373 0.982 0.052 
K4M 3 0.941 16.764 0.959 0.732 0.982 40.997 0.991 0.257 58.960 0.965 0.171 
K4M 9 0.990 13.075 0.986 0.250 0.993 30.579 0.994 0.554 28.138 0.993 0.069 
K100M 2 0.997 7.971 0.982 0.108 0.973 18.242 0.988 0.749 12.322 0.988 0.033 
K100M 3 0.944 16.422 0.981 0.487 0.981 39.311 0.984 0.401 45.674 0.987 0.127 
K100M 9 0.996 10.326 0.969 0.156 0.968 23.606 0.987 0.761 15.623 0.979 0.046 
E10FP 2 0.996 11.393 0.980 0.187 0.983 26.297 0.991 0.664 20.350 0.989 0.054 
E10FP 9 0.937 15.397 0.998 0.425 0.983 36.938 0.990 0.392 43.513 0.997 0.113 
KSR 2 0.989 11.920 0.973 0.202 0.976 27.493 0.985 0.673 20.987 0.982 0.057 
KSR 3 0.784 16.026 0.997 0.825 0.879 39.806 0.927 0.202 61.979 0.981 0.171 
KSR 9 0.944 13.861 0.999 0.318 0.987 33.152 0.991 0.411 37.952 0.996 0.085 
pH 6.8         
K4M 2 0.997 10.986 0.972 0.173 0.975 25.181 0.989 0.733 17.455 0.982 0.050 
K4M 3 0.948 16.217 0.968 0.561 0.983 39.362 0.989 0.302 53.009 0.968 0.144 
K4M 9 0.990 12.811 0.990 0.237 0.996 29.837 0.997 0.591 25.898 0.996 0.066 
K100M 2 0.998 7.769 0.985 0.104 0.974 17.638 0.994 0.836 10.336 0.990 0.031 
K100M 3 0.949 15.577 0.991 0.412 0.985 37.135 0.988 0.430 41.332 0.995 0.109 
K100M 9 0.995 10.075 0.969 0.149 0.967 22.928 0.988 0.812 13.960 0.978 0.044 
E10FP 2 0.994 11.092 0.982 0.179 0.984 25.538 0.992 0.689 19.001 0.989 0.051 
E10FP 9 0.935 14.844 0.999 0.381 0.982 35.546 0.988 0.406 41.007 0.997 0.101 
KSR 2 0.992 11.578 0.983 0.191 0.984 26.576 0.992 0.719 18.845 0.990 0.055 
KSR 3 0.797 15.700 0.985 0.610 0.889 38.587 0.925 0.272 54.335 0.980 0.156 
KSR 9 0.959 13.485 0.999 0.291 0.993 32.119 0.995 0.433 35.555 0.998 0.078
to identify the release mechanism of drug. Savaşer et al. 
used the same application for drug release mechanism 
evaluation from diclofenac sodium containing HPMC 
matrices (Savaşer, Özkan, Işmer, 2005), Roni, Kibria and 
Jalil (2009) applied equation for evaluation of controlled 
release alfuzosin tablets prepared with ethylcellulose and 
hydropropylmethylcellulose. El-Bagory et al. (2012) 
relate Korsmeyer-Peppas equation for release mechanism 
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TABLE V - Similarity Factor (f2) Values of Tizanidine formulations
Comparision f2 Dissolution Profile
0.1 N HCl  pH 4.5 pH 6.8
K100M9 and K4M2 69.28 65.69 65.80 Similar
K100M9 and K4M3 20.42 20.96 22.44 Dissimilar
K100M9 and K4M9 43.66 42.05 42.22 Dissimilar
K100M9 and K100M2 47.22 48.88 49.19 Dissimilar
K100M9 and K100M3 23.73 24.33 26.37 Dissimilar
K100M9 and E10FP2 66.04 60.97 59.94 Similar
K100M9 and E10FP9 26.00 27.33 28.24 Dissimilar
K100M9 and KSR2 55.27 53.27 54.19 Similar
K100M9 and KSR3 16.57 20.68 21.93 Dissimilar
K100M9 and KSR9 28.13 33.48 34.45 Dissimilar
TABLE VI - Stability studies and shelf life of Controlled release tizanidine formulations
Study 
Period
Test
Methocel K4M Methocel K100M Ethocel 10 FP Kollidon SR
K4M 2 K4M 3 K4M 9 K100M 2 K100M 3 K100M 9 E10FP 2 E10FP 9 KSR 2 KSR 3 KSR 9
0 Month
Hardness 
(kg)
4.81 ±
0.52
4.20 ±
0.38
4.69 ±
1.18
5.40 ±
0.68
4.30 ±
0.70
5.57 ±
0.76
12.92 ±
1.80
12.57 ±
2.30
5.01 ±
0.74
4.24 ±
0.88
4.20 ±
0.58
Friability 
(%)
0.76 0.91 0.94 0.57 0.85 0.63 0.30 0.47 0.29 0.84 0.63
*DT (Hrs) 4.82 4.18 4.30 6.87 4.95 6.58 5.72 5.13 7.52 4.25 6.27
Dissolution 
(%)
98.32 97.98 97.56 82.32 98.15 99.52 98.21 98.65 99.59 98.29 98.53
Assay (%) 98.76 97.25 98.05 98.37 97.82 98.87 98.79 98.24 98.39 96.51 97.27
1 Month
Hardness 
(kg)
4.79 ±
0.61
4.15 ±
0.24
4.62 ±
0.94
5.36 ±
0.83
4.21 ±
0.78
5.55 ±
0.39
12.73 ±
1.75
12.49 ±
2.00
4.98 ±
0.83
4.20 ±
0.95
4.17 ±
0.62
Friability 
(%)
0.77 0.91 0.94 0.68 0.9 0.65 0.38 0.54 0.35 0.87 0.69
*DT (Hrs) 4.78 4.04 4.25 6.82 4.78 6.51 5.64 5.03 7.18 4.03 5.93
Dissolution 
(%)
97.64 97.56 97.19 81.97 97.88 99.07 97.79 97.55 98.41 96.16 97.54
Assay (%) 98.53 96.79 97.64 98.08 97.34 98.51 98.32 97.86 98.17 95.87 96.82
3 Month
Hardness 
(kg)
4.76 ±
0.64
4.04 ±
0.73
4.58 ±
0.96
5.21 ±
0.88
4.13 ±
0.93
5.45 ±
0.86
12.45 ±
1.14
12.34 ±
2.20
4.96 ±
0.61
4.18 ±
0.56
4.02 ±
0.39
Friability 
(%)
0.81 0.93 0.97 0.63 0.94 0.69 0.42 0.63 0.42 0.93 0.78
*DT (Hrs) 4.63 3.97 4.13 6.71 4.71 6.48 5.48 4.97 6.43 3.93 5.67
Dissolution 
(%)
97.39 96.42 96.7 80.63 96.94 98.83 97.00 96.13 97.57 95.04 95.73
Assay (%) 97.96 96.24 97.11 97.64 96.82 98.16 97.87 97.02 97.4 95.29 95.99
6 Month
Hardness 
(kg)
4.68 ±
0.86
3.93 ±
0.65
4.53 ±
1.02
5.14 ±
0.93
4.01 ±
0.82
5.36 ±
0.54
12.30 ±
1.11
12.11 ±
1.64
4.83 ±
0.56
4.00 ±
0.98
3.79 ±
0.65
Friability 
(%)
0.87 0.97 0.99 0.69 0.97 0.74 0.55 0.78 0.59 1.08 0.85
*DT (Hrs) 4.58 3.85 4.05 6.59 4.63 6.36 5.37 4.86 6.07 3.72 5.10
Dissolution 
(%)
96.84 95.47 95.93 80.28 96.1 98.54 96.13 94.33 96.52 91.76 93.33
Assay (%) 97.84 95.73 96.85 97.38 96.51 98.02 97.46 96.77 96.83 94.83 95.00
Shelf Life (Months) 26.680 18.896 21.712 29.450 19.775 30.347 24.172 17.053 21.900 13.551 16.209
*DT = Disintegration time
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determination of theophylline matrix tablets prepared 
with Kollidon SR, Carnauba wax and ethylcellulose. 
Model independent method
Formulation K100M9 was considered as reference 
and f2 similarity test was performed for selected 
formulations. Dissolution profile was found to be similar 
for K4M2, E10FP2 and KSR2 (Table V). Comparison 
of dissolution profiles of drug through similarity test (f2) 
was used in other research studies for SR preparations 
(Dash et al., 2010; Shoaib et al., 2010; Salústio et al., 
2011).
Response surface analysis
Response surface models of effect of HPMC K4M 
and Avicel pH 101 are shown in Figure 5a, 5b and 5c. The 
3D plots clearly showed that polymer had greater influence 
on response as compared to Avicel pH 101. Disintegration 
time increased drastically with an increase in polymer 
concentration while Avicel has lesser effect in enhancing 
disintegration time as compare to HPMC K4M. Increase 
in HPMC K4M ratio in the formulation caused a steep 
decrease in the release in 2 hours and Avicel seems to 
produce not a very significant impact on matrix release. 
FIGURE 5a - Response surface model (RSM) showing effect 
of independent variables HPMC K4M and Avicel pH 101 on 
Disintegration time.
FIGURE 5b - Response surface model (RSM) showing effect 
of independent variables HPMC K4M and Avicel pH 101 on 
responses Drug release in 2 hours.
FIGURE 5c - Response surface model (RSM) showing effect of 
independent variables HPMC K4M and Avicel pH 101 on Drug 
release in 8 hours.
FIGURE 6a - Response surface model (RSM) showing effect 
of independent variables HPMC K100M and Avicel pH 101 on 
Disintegration time.
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FIGURE 6b - Response surface model (RSM) showing effect 
of independent variables HPMC K100M and Avicel pH 101 on 
Drug release in 2 hours.
FIGURE 6c - Response surface model (RSM) showing effect 
of independent variables HPMC K100M and Avicel pH 101 on 
Drug release in 8 hours.
FIGURE 7a - Response surface model (RSM) showing effect 
of independent variables Ethocel 10FP and Avicel pH 101 on 
Disintegration time.
FIGURE 7b - Response surface model (RSM) showing effect 
of independent variables Ethocel 10FP and Avicel pH 101 on 
Drug release in 2 hours.
FIGURE 7c - Response surface model (RSM) showing effect 
of independent variables Ethocel 10FP and Avicel pH 101 on 
Drug release in 8 hours.
At 8 hours, no prominent effect on release can be seen 
with HPMC K4M change and a near to linear response 
found with change in Avicel pH101. Similar responses 
were observed with HPMC K100M for disintegration time 
and release at 2 hours while release at 8 hours has been 
significantly influenced with increase in HPMC K100M 
as presented in Figure 6a, 6b and 6c. RSM for Ethocel 
10FP effect on responses were shown in Figure 7. It can 
be clearly seen that increase in concentration of polymer 
caused an increase in disintegration time and Avicel did 
not produce any significant change in disintegration time 
(Figure 7a, 7b and 7c). There was a declining response in 
release of the drug at 2 hours and 8 hours with an increase 
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(ICH, 2003). Formulation K4M2, K4M3, K4M9, 
K100M2, K100M3, K100M9, E10FP2, E10FP9, KSR2, 
KSR3 and KSR9 were evaluated for quality attribute, shelf 
life were calculated using software R-Gui version 2.15.2 
(stab) and results were given in Table VI. It was found 
that all formulations were within the acceptable limits for 
physical and chemical parameter but formulations K4M3 
and KSR3 were failed for disintegration time and friability. 
It was found that formulations K4M2, K100M2, K100M9 
(highest shelf life: 30.347 months) and E10FP2 had the 
shelf life of more than 24 months and were considered as 
stable formulations.
CONCLUSION
Tizanidine hydrochloride formulations with 
controlled release characteristics were prepared by using 
HPMC K4M and K100M, Ethocel 10FP and Kollidon SR.
It was observed that the formulations with polymer 
contents lesser than 40% remained ineffective in 
controlling the release of drug however, satisfactory 
release profiles were obtained with HPMC K4M (K4M2) 
50%, K100M (K100M9) 40%, Ethocel 10FP (E10FP2) 
40% and Kollidon SR (KSR2) 55%. Formulation K100M9 
with HPMC K100M showed highest shelf life of 30.347 
months. Therefore, it can be concluded that controlled 
release tizanidine hydrochloride tablets can effectively 
be prepared by using these polymers through direct 
compression method. Moreover, formulation K100M9 
was found to be the best formulation for controlled release 
tizanidine.
FIGURE 8a - Response surface model (RSM) showing effect 
of independent variables Kollidon SR and Avicel pH 101 on 
Disintegration time.
FIGURE 8b - Response surface model (RSM) showing effect of 
independent variables Kollidon SR and Avicel pH 101 on Drug 
release in 2 hours.
FIGURE 8c - Response surface model (RSM) showing effect of 
independent variables Kollidon SR and Avicel pH 101 on Drug 
release in 8 hours.
in Ethocel 10FP proportion in the formulation (Figure 
7b and 7c). Kollidon SR produced expected response of 
increase in disintegration time with increase in polymer 
concentration. An inverse relationship found between 
Kollidon SR proportion and release at 2 and 8 hours 
(Figure 8b and 8c). Bose, Wong and Singh (2012) found 
similar type of effect of HPMC K100M on Itopride SR 
matrix tablet release.
Stability evaluation
The formulations showing disintegration time 
greater than 4 hours were subjected to accelerated stability 
studies for 0, 1, 3 and 6 months following ICH guidelines 
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